Marklyn Jones, MD
Urology · Highlands Ranch, CONPI 1003859075
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (34.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 77.7% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2023 at $9,658 and has fallen 78.7% since, to $2,053 in 2025.
Across 235 payments — averaging $80.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$15K
- Histosonics, Inc.$603
- AbbVie$569
- Johnson & Johnson$440
- Sumitomo Pharma America, Inc.$265
- Astellas Pharma US Inc$202
- plus $2K from 34 others
What the payments were for
- Speaking & faculty fees$1,6959%
- Travel & lodging$4,61224%
- Food & beverage$5,95331%
- Education$6,57135%
- Gifts$1741%
- Entertainment$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 71 | $14,783 |
| Histosonics, Inc. | 2 | $603 |
| AbbVie(2 entities) | 34 | $569 |
| Johnson & Johnson | 19 | $440 |
| Sumitomo Pharma America, Inc. | 10 | $265 |
| Astellas Pharma US Inc | 9 | $202 |
| Telix Pharmaceuticals | 9 | $180 |
| Bayer | 9 | $171 |
| SRS Medical Systems, Inc. | 1 | $167 |
| Pfizer | 8 | $152 |
| Myriad Genetic Laboratories, Inc. | 3 | $144 |
| Myovant Sciences Inc. | 6 | $138 |
| Procept Biorobotics Corporation | 1 | $112 |
| Merck | 5 | $103 |
| Progenics Pharmaceuticals, Inc. | 4 | $91 |
| Boston Scientific | 4 | $90 |
| Amgen | 4 | $83 |
| Urovant Sciences Inc | 3 | $62 |
| Endo Pharmaceuticals Inc. | 3 | $58 |
| Urogen Pharma, Inc. | 3 | $52 |
| Blue Earth Diagnostics | 2 | $49 |
| Axonics, Inc. | 1 | $48 |
| Mimedx Group, Inc. | 2 | $46 |
| Travere Therapeutics, Inc. | 3 | $46 |
| Dendreon Pharmaceuticals LLC | 1 | $33 |
| EMD Serono, Inc. | 1 | $33 |
| Novartis | 2 | $33 |
| Olympus America Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
| Endo USA, Inc. | 1 | $28 |
| 180 Medical, Inc. | 1 | $28 |
| Rochester Medical Corporation | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| AstraZeneca | 1 | $21 |
| Coloplast | 1 | $20 |
| Novo Nordisk | 1 | $20 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Hitachi Healthcare Americas Corp. | 1 | $15 |
| Tolmar Pharmaceuticals, Inc. | 1 | $12 |
| Clarus Therapeutics Inc. | 2 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$10,078
- DA VINCI SP$3,464
- CT3000 Pro Base Unit$167
- UroCuff-DC Disposable, Single$167
- Prolaris$117
- AquaBeam Robotic System$112
How this compares
$19,019 in reported general payments places this provider in the 85th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 22 | $21,203 |
| Testosterone | 30 | $3,325 |
| Tamsulosin Hcl | 190 | $2,833 |
| Finasteride | 161 | $2,419 |
| Testosterone Cypionate | 42 | $1,066 |
| Solifenacin Succinate | 17 | $878 |
| Dutasteride | 20 | $830 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 26 | $546 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 37 | $171 |
| Oxycodone Hcl | 45 | $128 |
| Levofloxacin | 16 | $39 |
| Diazepam | 21 | $18 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $202 | $21,20322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 225 urology providers in Colorado.
Other urology in Highlands Ranch
- Austin DerosaHighlands Ranch$7K
- Lawrence KarshDenver$706K
- Alexandra RogersLafayette$476K
- Derek ZukoskyGolden$442K
- James McBrideDurango$234K
- Damian SorceParker$224K
- Suzanne MerrillLone Tree$102K
- Ali SarramLone Tree$76K
- John KeferBoulder$68K
- Garrick GreearLongmont$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.